Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
University of Southern California
Zhejiang Cancer Hospital
Taiho Pharmaceutical Co., Ltd.
Fifth Affiliated Hospital, Sun Yat-Sen University
Seagen Inc.
Gossamer Bio Inc.
Jiangsu HengRui Medicine Co., Ltd.
Jiangsu HengRui Medicine Co., Ltd.
AstraZeneca
China Medical University Hospital
Xiangya Hospital of Central South University
Masonic Cancer Center, University of Minnesota
Altor BioScience
Chang Gung Memorial Hospital
University of Kentucky
National Cancer Institute (NCI)
Dartmouth-Hitchcock Medical Center